3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Spinocerebellar Degenerations
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
44
Fluorouracil
16
Cisplatin
15
Oxaliplatin
13
Capecitabine
11
Paclitaxel
10
lenvatinib
8
Leucovorin
8
Irinotecan
6
Docetaxel
6
trifluridine tipiracil drug combination
3
regorafenib
3
Saline Solution
3
Levoleucovorin
3
Gemcitabine
3
Bevacizumab
3
patritumab deruxtecan
2
Trastuzumab
2
S 1 (combination)
2
Radiotherapy
2
Cetuximab
2
Carboplatin
2
zanidatamab
1
vicriviroc
1
tremelimumab
1
tislelizumab
1
tipiracil
1
spartalizumab
1
sinoporphyrin sodium
1
ribociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
vicriviroc
×
Gastrointestinal
×
Clear all
NCT03631407
2024-11-21
MK-7690-046
Merck Sharp & Dohme LLC
Phase 2
Completed
41 enrolled
20 charts